The common, VTE-protective, G haplotype of F5 increases factor V-short, TFPI function, and risk of bleeding.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
04 Oct 2024
Historique:
accepted: 15 09 2024
received: 10 07 2024
revised: 28 08 2024
medline: 4 10 2024
pubmed: 4 10 2024
entrez: 4 10 2024
Statut: aheadofprint

Résumé

The G haplotype is a group of co-inherited single nucleotide variants in the F5 gene that reduce venous thromboembolism (VTE) risk. Even though seven percent of the population is homozygous for the G haplotype (F5-G/G), the underlying mechanism of VTE protection is poorly understood. Using RNA-seq data from 4,651 blood donors in the INTERVAL study we detected a rare excision event at the FV-short splice sites in 5% of F5-G/Gs as compared with 2.16% of homozygotes for the F5 reference sequence (F5-ref) (p=0.003). Highly elevated (~10-fold) FV-short, an FV isoform lacking most of the B-domain, has been linked with increased tissue factor inhibitor alpha (TFPIα) levels in rare hemorrhagic diathesis including East Texas Bleeding Disorder. To ascertain whether the enhanced FV-short splicing seen in F5-G/G INTERVAL participants translated to increased plasma FV-short levels we analyzed plasma samples from 7 F5-G/G and 13 F5-ref individuals in a recall-by-genotype study. A ~2.2-fold higher amount of FV-short was found in a plasma pool from F5-G/G participants as compared with F5-refs (p=0.029), but no difference in total FV levels. Whilst no significant difference in TFPI levels were found, F5-G/Gs showed a ~1.4-fold TFPI-dependent increase in lag time to thrombin generation compared to F5-refs (p=0.0085). Finally, in an analysis of 117,699 UK Biobank participants we discovered that, while being protective against VTE, the G haplotype also confers an increase in bleeding episodes (p=0.011). Our study provides evidence that the effect of the common G haplotype is mediated by the FV-short/TFPI pathway.

Identifiants

pubmed: 39365993
pii: 518047
doi: 10.1182/bloodadvances.2024014020
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 American Society of Hematology.

Auteurs

Matthew Christopher Sims (MC)

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.

Magdalena Gierula (M)

Imperial college, London, United Kingdom.

Jonathan C Stephens (JC)

University of Cambridge, Cambridge, United Kingdom.

Alex Tokolyi (A)

Wellcome Sanger Institute, Hinxton, United Kingdom.

Luca Stefanucci (L)

University of Cambridge, Cambridge, United Kingdom.

Elodie Persyn (E)

University of Cambridge, Cambridge, United Kingdom.

Luanluan Sun (L)

BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, Cambridge, United Kingdom.

Emma Davenport (E)

Wellcome Sanger Institute, Hinxton, United Kingdom.

Emanuele Di Angelantonio (E)

University of Cambridge, Cambridge, United Kingdom.

Kate Downes (K)

University of Cambridge, Cambridge, United Kingdom.

Michael Inouye (M)

BHF Cardiovascular Epidemiology Unit, Cambridge, United Kingdom.

Dirk S Paul (DS)

University of Cambridge, Cambridge, United Kingdom.

William Thomas (W)

Addenbrooke's Hospital, Cambridge, United Kingdom.

Alexander Tolios (A)

Medical University of Vienna, Vienna, Austria.

Nihr BioResource (N)

NIHR BioResource, Cambridge, United Kingdom.

Willem H Ouwehand (WH)

University of Cambridge, Cambridge, United Kingdom.

Nicholas S Gleadall (NS)

University of Cambridge, Cambridge, United Kingdom.

James T B Crawley (JTB)

Imperial College London, London, United Kingdom.

Adam S Butterworth (AS)

University of Cambridge, Cambridge, United Kingdom.

Mattia Frontini (M)

University of Exeter, Exeter, United Kingdom.

Josefin Ahnstrom (J)

Imperial College London, London, United Kingdom.

Classifications MeSH